nonlin fit Search Results


nonlin fit range graphpad prizm 6.01 software  (GraphPad Software Inc)
90
GraphPad Software Inc nonlin fit range graphpad prizm 6.01 software
Nonlin Fit Range Graphpad Prizm 6.01 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonlin fit range graphpad prizm 6.01 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
nonlin fit range graphpad prizm 6.01 software - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
nonlin fit  (GraphPad Software Inc)
90
GraphPad Software Inc nonlin fit
Nonlin Fit, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonlin fit/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
nonlin fit - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
nonliner regression (curve fit) of xy analyses  (GraphPad Software Inc)
90
GraphPad Software Inc nonliner regression (curve fit) of xy analyses
Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad <t>Prism’s</t> Nonliner regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.
Nonliner Regression (Curve Fit) Of Xy Analyses, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonliner regression (curve fit) of xy analyses/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
nonliner regression (curve fit) of xy analyses - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
nonlin fit graphpad prism 8.0.2  (GraphPad Software Inc)
90
GraphPad Software Inc nonlin fit graphpad prism 8.0.2
Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad <t>Prism’s</t> Nonliner regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.
Nonlin Fit Graphpad Prism 8.0.2, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonlin fit graphpad prism 8.0.2/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
nonlin fit graphpad prism 8.0.2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
prism’s nonliner regression  (GraphPad Software Inc)
90
GraphPad Software Inc prism’s nonliner regression
Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad Prism’s <t>Nonliner</t> regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.
Prism’s Nonliner Regression, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism’s nonliner regression/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism’s nonliner regression - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
prism function ‘nonlin fit:log(agonist) vs. response – variable slope  (GraphPad Software Inc)
90
GraphPad Software Inc prism function ‘nonlin fit:log(agonist) vs. response – variable slope
Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad Prism’s <t>Nonliner</t> regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.
Prism Function ‘Nonlin Fit:Log(agonist) Vs. Response – Variable Slope, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism function ‘nonlin fit:log(agonist) vs. response – variable slope/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism function ‘nonlin fit:log(agonist) vs. response – variable slope - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad Prism’s Nonliner regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.

Journal: Frontiers in Immunology

Article Title: A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo

doi: 10.3389/fimmu.2022.831536

Figure Lengend Snippet: Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad Prism’s Nonliner regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.

Article Snippet: IC50 values were calculated using GraphPad Prism’s Nonliner regression (curve fit) of XY analyses with the formula Y=Bottom+(Top-Bottom)/(1 + 10^((LogIC50-X) ×HillSlope)).

Techniques: Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Inhibition, Recombinant, In Vitro, Positive Control, Negative Control, Concentration Assay

Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad Prism’s Nonliner regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.

Journal: Frontiers in Immunology

Article Title: A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo

doi: 10.3389/fimmu.2022.831536

Figure Lengend Snippet: Binding and neutralizing activity of humanized anti-Abrin antibody S008. (A) S008 binds to abrin in a dose-dependent manner determined by ELISA. Absorbance values for different antibody concentrations (0.005 to 5 μg/mL) were detected at 450 nm. The EC50 value of S008 was 0.317 μg/mL, while that of 10D8 was 0.553 μg/mL, and EC50 values were calculated using GraphPad Prism’s Nonliner regression (curve fit) of XY analyses; (B) Kinetic analysis of antibody binding to abrin measured by the ForteBio method. Left: 10D8 (KD=0.2836 nmol/L); right: S008 (KD=0.2095 nmol/L). (C) Inhibition rate of protein synthesis induced by diluted recombinant abrin A chain treatment. The IC50 of protein synthesis in vitro was determined to be 0.01 μg/mL; (D) S008 and 10D8 neutralized the A chain and recovered protein synthesis in a dose-dependent manner. Left: luminescence values of 10D8 and S008. Positive control without abrin A chain, negative control without antibodies. (** P < 0.01, *** P < 0.001; ns, no significance). Right: Rates of protein synthesis by 10D8 and S008 were calculated using the equation (RLU of the experimental group)/(RLU of positive control group) ×100%. (E) Effect of different concentration of abrin on cell death. (F) S008 protected both Jurkat (left) and Vero (right) cells against abrin toxicity in a dose-dependent manner.

Article Snippet: IC50 values were calculated using GraphPad Prism’s Nonliner regression (curve fit) of XY analyses with the formula Y=Bottom+(Top-Bottom)/(1 + 10^((LogIC50-X) ×HillSlope)).

Techniques: Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Inhibition, Recombinant, In Vitro, Positive Control, Negative Control, Concentration Assay